In last trading session, Blueprint Medicines Corp (NASDAQ:BPMC) saw 0.89 million shares changing hands with its beta currently measuring 0.63. Company’s recent per share price level of $63.66 trading at $1.04 or 1.66% at ring of the bell on the day assigns it a market valuation of $3.87B. That closing price of BPMC’s stock is at a discount of -6.82% from its 52-week high price of $68.00 and is indicating a premium of 40.59% from its 52-week low price of $37.82. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.74 million shares which gives us an average trading volume of 623.31K if we extend that period to 3-months.
For Blueprint Medicines Corp (BPMC), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 1.79. Splitting up the data highlights that, out of 19 analysts covering the stock, 2 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 3 suggested the stock as a Hold whereas 13 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$2.04 in the current quarter.
Blueprint Medicines Corp (NASDAQ:BPMC) trade information
Upright in the green during last session for gaining 1.66%, in the last five days BPMC remained trading in the green while hitting it’s week-highest on Wednesday, 11/15/23 when the stock touched $63.66 price level, adding 2.9% to its value on the day. Blueprint Medicines Corp’s shares saw a change of 45.31% in year-to-date performance and have moved 8.17% in past 5-day. Blueprint Medicines Corp (NASDAQ:BPMC) showed a performance of 38.21% in past 30-days. Number of shares sold short was 4.45 million shares which calculate 5.55 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $79.50 to the stock, which implies a rise of 19.92% to its current value. Analysts have been projecting $50.00 as a low price target for the stock while placing it at a high target of $114.00. It follows that stock’s current price would drop -79.08% in reaching the projected high whereas dropping to the targeted low would mean a gain of 21.46% for stock’s current value.
Blueprint Medicines Corp (BPMC) estimates and forecasts
Statistics highlight that Blueprint Medicines Corp is scoring comparatively lower than the scores of other players of the relevant industry. The company added 16.30% of value to its shares in past 6 months, showing an annual growth rate of 9.30% while that of industry is 14.80. Apart from that, the company came raising its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to increase by 23.00% in the current quarter and calculating 19.10% increase in the next quarter. This year revenue growth is estimated to rise 19.10% from the last financial year’s standing.
16 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $66.81 million for the same. And 11 analysts are in estimates of company making revenue of $76.3 million in the next quarter that will end on Mar 2024. Company posted $38.78 million and $63.29 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 72.30% while estimating it to be 20.60% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -18.98% during past 5 years.
Blueprint Medicines Corp is more likely to be releasing its next quarterly report between February 14 and February 19 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Blueprint Medicines Corp (NASDAQ:BPMC)’s Major holders
Insiders are in possession of 0.77% of company’s total shares while institution are holding 107.13 percent of that, with stock having share float percentage of 107.96%. Investors also watch the number of corporate investors in a company very closely, which is 107.13% institutions for Blueprint Medicines Corp that are currently holding shares of the company. FMR, LLC is the top institutional holder at BPMC for having 6.71 million shares of worth $423.95 million. And as of Jun 29, 2023, it was holding 11.06% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 6.54 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 10.77% of outstanding shares, having a total worth of $413.06 million.
On the other hand, Vanguard Specialized-Health Care Fund and Price (T.Rowe) New Horizons Fund are the top two Mutual Funds which own company’s shares. As of Jul 30, 2023, the former fund manager was holding 2.38 million shares of worth $157.02 million or 3.92% of the total outstanding shares. The later fund manager was in possession of 2.1 million shares on Jun 29, 2023, making its stake of worth around $132.7 million in the company or a holder of 3.46% of company’s stock.